<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64691</article-id><article-id pub-id-type="doi">10.26442/00403660.2021.02.200602</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Enteropathy with impaired membrane digestion and the prospects for cytoprotective therapy</article-title><trans-title-group xml:lang="ru"><trans-title>Энтеропатия с нарушением мембранного пищеварения и перспективы цитопротективной терапии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9782-4860</contrib-id><name-alternatives><name xml:lang="en"><surname>Parfenov</surname><given-names>A. I.</given-names></name><name xml:lang="ru"><surname>Парфенов</surname><given-names>Асфольд Иванович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., проф., зав. отд. патологии кишечника</p></bio><email>asfold@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7519-2041</contrib-id><name-alternatives><name xml:lang="en"><surname>Akhmadullina</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Ахмадуллина</surname><given-names>Ольга Валентиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>к.м.н., мл. науч. сотр. отд-ния невоспалительной патологии кишечника</p></bio><email>asfold@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4400-1227</contrib-id><name-alternatives><name xml:lang="en"><surname>Belostotsky</surname><given-names>N. I.</given-names></name><name xml:lang="ru"><surname>Белостоцкий</surname><given-names>Николай Игоревич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., ст. науч. сотр. лаб. доклинических методов исследования</p></bio><email>asfold@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7519-2041</contrib-id><name-alternatives><name xml:lang="en"><surname>Sabelnikova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Сабельникова</surname><given-names>Елена Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., ст. науч. сотр. отд-ния невоспалительной патологии кишечника, зам. дир. по научной работе</p></bio><email>asfold@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2738-2956</contrib-id><name-alternatives><name xml:lang="en"><surname>Novikov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Новиков</surname><given-names>Александр Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.б.н., вед. науч. сотр. лаб. клинической иммунологии</p></bio><email>asfold@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9576-2953</contrib-id><name-alternatives><name xml:lang="en"><surname>Bykova</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Быкова</surname><given-names>Светлана Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>к.м.н., зав. отд-нием невоспалительной патологии кишечника</p></bio><email>asfold@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6516-7782</contrib-id><name-alternatives><name xml:lang="en"><surname>Dbar</surname><given-names>S. R.</given-names></name><name xml:lang="ru"><surname>Дбар</surname><given-names>Сариа Романовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>мл. науч. сотр. отд-ния невоспалительной патологии кишечника</p></bio><email>asfold@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Loginov Moscow Clinical Scientific Center</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2021</year></pub-date><volume>93</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>129</fpage><lpage>137</lpage><history><date date-type="received" iso-8601-date="2021-04-05"><day>05</day><month>04</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-04-05"><day>05</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/64691">https://ter-arkhiv.ru/0040-3660/article/view/64691</self-uri><abstract xml:lang="en"><p>The article describes enteropathy with impaired membrane digestion (EIMD) as a new nosological form. The main clinical manifestation of EIMD is the poor tolerance of food products, in particular carbohydrates and a decrease in the activity of membrane enzymes, in particular, carbohydrates, in the mucous membrane of the small intestine. The cause of the disease can be acute intestinal infections, viruses, drugs and other agents that damage the small intestine. The pathophysiology, clinical picture and diagnosis of EIMD are described. The basis of therapy is rebamipide, which has the ability to reduce the symptoms of carbohydrate intolerance and increase the activity of disaccharidases.</p></abstract><trans-abstract xml:lang="ru"><p>В статье описана энтеропатия с нарушением мембранного пищеварения (ЭНМП) как новая нозологическая форма. Основным клиническим проявлением ЭНМП являются плохая переносимость пищевых продуктов, в особенности углеводов, и снижение активности мембранных ферментов, в частности карбогидраз, в слизистой оболочке тонкой кишки (СОТК). Причиной болезни могут быть острые кишечные инфекции, вирусы, лекарственные препараты и другие агенты, повреждающие СОТК. Изложены патофизиология, классификация, клиническая картина и диагностика ЭНМП. Основу терапии составляет ребамипид, обладающий свойством уменьшать симптомы непереносимости углеводов и повышать активность дисахаридаз СОТК.</p></trans-abstract><kwd-group xml:lang="en"><kwd>membrane digestion</kwd><kwd>enteropathy with impaired membrane digestion</kwd><kwd>disaccharidase</kwd><kwd>peptidase</kwd><kwd>disaccharidase deficiency</kwd><kwd>diagnosis</kwd><kwd>treatment</kwd><kwd>rebamipid</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мембранное пищеварение</kwd><kwd>энтеропатия с нарушением мембранного пищеварения</kwd><kwd>дисахаридазы</kwd><kwd>пептидазы</kwd><kwd>дисахаридазная недостаточность</kwd><kwd>диагностика</kwd><kwd>лечение</kwd><kwd>ребамипид</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Уголев А.М. Мембранное пищеварение. Л.: Наука, 1972 [Ugolev AM. Membrane digestion. Leningrad: Science, 1972 (In Russ.)].</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Crawley S, Mooseker M, Tyska M. Shaping the intestinal brush border. J Cell Biol. 2014;207:441-51. doi: 10.1083/jcb.201407015</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Crawley SW, Shifrin DA Jr, Grega-Larson NE, et al. Intestinal brush border assembly driven by protocadherin-based intermicrovillar adhesion. Cell. 2014;157:433-46. doi: 10.1016/ j.cell.2014.01.067</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Уголев А.М. Эволюция пищеварения и принципы эволюции функций. Л.: Наука, 1985 [Ugolev AM. The evolution of digestion and the principles of the evolution of functions. Leningrad: Science, 1985 (In Russ.)].</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Рыбальченко О.В., Бондаренко В.М. Образование биопленок симбионтными представителями микробиоты кишечника как форма существования бактерий. Вестник СПбГУ. 2013;1:179-86 [Rybalchenko OV, Bondarenko VM. The formation of biofilms by symbiont representatives of the intestinal microbiota as a form of the existence of bacteria. Bulletin of Saint Petersburg State University. 2013;1:179-86 (In Russ.)].</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Butterworth PJ, Warren FJ, Ellis PR. Human α-amylase and starch digestion: An interesting marriage. Starch. 2011;63(7):395-405. doi: 10.1002/star.201000150</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Burke M. Carbohydrate Intolerance and Disaccharidase Measurement. Clin Biochem Rev. 2019;40(4):167-74. doi: 10.33176/AACB-19-00025</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Amiri M, Naim HY. Characterization of mucosal disaccharidases from human intestine. Nutrients. 2017;9:E1106. doi: 10.3390/nu9101106</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Treem WR. Clinical aspects an treatment of congenital sucrase-isomaltase deifiency. J Pediatr Gastroenterol Nutr. 2012;55:S7-13. doi: 10.1097/01.mpg.0000421401.57633.90</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Robayo-Torres CC, Quezada-Calvillo R, Nichols BL. Disaccharide digestion: clinical and molecular aspects. Clin Gastroenterol Hepatol. 2006;4(3):276-87. doi: 10.1016/j.cgh.2005.12.023</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Williams BL, Hornig M, Buie T, et al. Impaired Carbohydrate Digestion and Transport and Mucosal Dysbiosis in the Intestines of Children with Autism and Gastrointestinal Disturbances. PLoS One. 2011;6(9):e24585. doi: 1371/journal.pone.0024585</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Маев И.В., Кучерявый Ю.А. Болезни поджелудочной железы. Т. 2. М.: Медицина, Шико, 2008 [Maev IV, Kucheryavy YuA. Diseases of the pancreas. Vol. 2. Moscow: Medicine, Shiko, 2008 (In Russ.)].</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Парфенов А.И. Энтеропатия с нарушением мембранного пищеварения. М.: Медконгресс, 2019 [Parfenov AI. Enteropathy with impaired membrane digestion. Moscow: Medkongress, 2019 (In Russ.)].</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Фролькис А.В. Энтеральная недостаточность. М.: Наука, 1989 [Frolkis AV. Enteric insufficiency. Moscow: Nauka, 1989 (In Russ.)].</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Thiagarajah JR, Kamin DS, Acra S, et al.; PediCODE Consortium. Advances in Evaluation of Chronic Diarrhea in Infants. Gastroenterology. 2018;154(8):2045-59.e6. doi: 10.1053/j.gastro.2018.03.067</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55-9. doi: 10.1016/s1542-3565(04)00603-2</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Карева Е.Н. Энтеропатия, ассоциированная с нестероидными противовоспалительными препаратами (НПВПэнтеропатия). Терапевтический архив. 2020;92(2):85-92 [Kareva EN. NSAID enteropathy. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):85-92 (In Russ.)]. doi: 10.26442/00403660.2020.02.000453</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Minai-Tehrani D, Minoui S, Sepehre M, et al. Inhibitory effect of codeine on sucrase activity. Drug Metab Lett. 2009;3(1):58-6. doi: 10.2174/187231209787176362</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Minai-Tehrani D, Ghaffari M, Sobhani-Damavandifar Z, et al. Ranitidine induces inhibition and structural changes in sucrase. J Enzyme Inhib Med Chem. 2012;27(4):553-57. doi: 10.3109/14756366.2011.601414</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018,66:e1-e48. doi: 10.1093/cid/cix1085</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Шелыгин Ю.А., Алешкин В.А., Сухина М.А. и др. Клинические рекомендации по диагностике, лечению и профилактике Clostridium difficile-ассоциированной диареи. Клинические рекомендации. М., 2017 [Shelygin YuA, Aleshkin VA, Sukhina MA, et al. Clinical recommendations for the diagnosis, treatment and prevention of Clostridium difficile-associated diarrhea. Clinical recommendations. Moscow, 2017 (In Russ.)].</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Litao G, Jingjing S, Yu L, et al. Risk factors for antibiotic-associated diarrhea in critically ill patients. Med Sci Monit. 2018;24:5000-7. doi: 10.12659/MSM.911308</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Tian CF, Su BY, Li YJ, et al. Management of antibiotic-associated pseudomembranous colitis in non-hospitalized and hospitalized patients. Pak J Pharm Sci. 2016;29(5 Suppl):1805-10.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Murray IA, Smith JA, Coupland K, et al. Intestinal disaccharidase deficiency without villous atrophy may represent early celiac disease. Scand J Gastroenterol. 2001;36(2):163-8. doi: 10.1080/003655201750065915</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Prasad KK, Thapa BR, Nain CK, et al. Brush border enzyme activities in relation to histological lesion in pediatric celiac disease. J Gastroenterol Hepatol. 2008;23(8):E348-52. doi: 10.1111/j.1440-1746.2007.05248.x</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Парфенов А.И., Ахмадуллина О.В., Белостоцкий Н.И. и др. Активность карбогидраз как маркер восстановления слизистой оболочки тонкой кишки у больных целиакией. Терапевтический архив. 2015;87(2):24-9 [Parfenov AI, Akhmadullina OV, Sabelnikova EA, et al. Carbohydrase activities may serve as a marker for small intestinal mucosal recovery in patients with celiac disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2015;87(2):24-9 (In Russ.)]. doi: 10.17116/terarkh201587224-29</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Богомолов П.О., Еремина Е.Ю., Тимофеева Н.М. и др. Активность пищеварительных ферментов в биоптатах тонкой кишки при патологии ЖКТ. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 1996;5(3):87-8 [Bogomolov PO, Eremina EYu, Timofeeva NM, et al. The activity of digestive enzymes in biopsy specimens of the small intestine in gastrointestinal tract pathology. Rus J Gastroenterol Hepatol Coloproctol. 1996;5(3):87-8 (In Russ.)].</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329-42. doi: 10.1038/nri3661</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Taylor C, Hodgson K, Sharpstone D, et al. The prevalence and severity of intestinal disaccharidase deficiency in human immunodeficiency virus-infected subjects. Scand J Gastroenterol. 2000;35(6):599-606. doi: 10.1080/003655200750023552</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Sharpstone D, Neild P, Crane R, et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut. 1999;45(1):70-6.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Heise C, Miller CJ, Lackner A, Dandekar S. Primary acute simian immunodeficiency virus-infection of intestinal lymphoid-tissue is associated with gastrointestinal dysfunction. J Infect Dis. 1994;169(5):1116-20.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Jourdan N, Brunet JP, Sapin C, et al. Rotavirus infection reduces sucraseisomaltase expression in human intestinal epithelial cells by perturbing protein targeting and organization of microvillar cytoskeleton. J Virol. 1998;72(9):7228-36.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Chopra P, Verma D, Khullar M, et al. Shiga toxin exposure modulates intestinal brush border membrane functional proteins in rabbit ileum. Mol Cell Biochem. 2006;283(1-2):85-92. doi: 10.1007/s11010-006-2347-x</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Varga J, Toth S Jr, Toth S, et al. The relationship between morphology and disaccharidase activity in ischemia reperfusion injured intestine. Acta Biochim Pol. 2012;59(4):631-8.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Boudry G, Jury J, Yang PC, Perdue MH. Chronic psychological stress alters epithelial cell turn-over in rat ileum. Am J Physiol Gastrointest Liver Physiol. 2007;292(5):G1228-32. doi: 10.1152/ajpgi.00358.2006</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Gericke B, Amiri M, Naim HY. The multiple roles of sucrase-isomaltase in the intestinal physiology. Mol Cell Pediatr. 2016;3(1):2. doi: 10.1186/s40348-016-0033-y</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Amiri M, Naim HY. Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of alpha-glucosidases, but not betagalactosidases. J Inherit Metab Dis. 2012;35(6):949-54. doi: 10.1007/s10545-012-9523-9</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Хаитов Р.М., Игнатьева Г.А., Сидорович И.Г. Иммунология. М.: Медицина, 2000 [Khaitov RM, Ignatieva GA, Sidorovich IG. Immunology. Moscow: Medicine, 2000 (In Russ.)].</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Amit-Romach E, Reifen R, Uni Z. Mucosal function in rat jejunum and ileum is altered by induction of colitis. Int J Mol Med. 2006;18(4):721-7.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Парфенов А.И., Ахмадуллина О.В., Белостоцкий Н.И. и др. Дисахаридазная недостаточность – одна из причин функциональных заболеваний кишечника. Клиническая медицина. 2018;96(4):365-70 [Parfenov АI, Ahmadullina OV, Belostoskij NI, et al. Disaharidase deficiency – is one of the causes of functional disorders of intestine. Clin Med. 2018;96(4):365-70 (In Russ.)]. doi: 10.18821/0023-2149-2018-96-4-365-370</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Парфенов А.И. Значение еюноперфузии в диагностике нарушений кишечного пищеварения и всасывания. Военно-мед. журн. 1987;10:26-30 [Parfenov AI. Importance of jeunoperfusion in the diagnosis of intestinal digestion and absorption. Voenno-Med Zhurnal. 1987;10:26-30 (In Russ.)].</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Парфенов А.И. Синдром нарушенной ассимиляции пищевых веществ. Рус. мед. журн. 2012;5(1):194-8 [Parfenov AI. Syndrome of impaired assimilation of nutrients. Russian Medical Journal. 2012;5(1):194-8 (In Russ.)].</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Парфенов А.И., Ахмадуллина О.В., Сабельникова Е.А. и др. Дисахаридазная недостаточность и функциональные заболевания кишечника. Терапевтический архив. 2017;89(4):45-52 [Parfenov AI, Akhmadullina OV, Sabelnikova EA, et al. Disaccharidase deficiency and functional bowel diseases. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(4):45-52 (In Russ.)]. doi: 10.17116/terarkh201789445-52</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Парфенов А.И., Акопова А.О., Щербаков П.Л., Михеева О.М. Место видеокапсульной эндоскопии в алгоритме диагностики болезни Крона тонкой кишки. Терапевтический архив. 2019;91(4):37-42 [Parfenov AI, Akopova AO, Shcherbakov PL, Mikcheeva OM. Role of video capsula endoscopy in the diagnostic algorithm of small bowel Crohn’s disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(4):37-42 (In Russ.)]. doi: 10.26442/00403660.2019.04.000079</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutrition Dietetics. 2011;24:487-95. doi: 10.1111/j.1365-277X.2011.01162</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol. 2013;108:707-17. doi: 10.1038/ajg.2013.96</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Ручкина И.Н., Фадеева Н.А., Парфенов А.И. и др. Роль микрофлоры тонкой кишки в развитии вторичной лактазной недостаточности и возможности ее лечения пробиотиками. Терапевтический архив. 2013;85(2):21-6 [Ruchkina IN, Fadeeva NA, Parfenov AI, et al. The role of the small bowel microflora in the development of secondary lactase deficiency and the possibilities of its treatment with probiotics. Terapevticheskii Arkhiv (Ter. Arkh.). 2013;85(2):21-6 (In Russ.)].</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Симаненков В.И., Тихонов С.В. Ребамипид – новые возможности гастроэнтеропротекции. Терапевтический архив. 2015;87(12):134-7 [Simanenkov VI, Tikhonov SV. Rebamipide: New opportunities of gastroenteroprotection. Terapevticheskii Arkhiv (Ter. Arkh.). 2015;87(12):134-7 (In Russ.)]. doi: 10.17116/terarkh20158712134-137</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Звяглова М.Ю., Князев О.В., Парфенов А.И. Фармакологический и клинический профиль ребамипида: новые терапевтические мишени. Терапевтический архив. 2020;92(2):104-11 [Zvyaglova MYu, Knyazev OV, Parfenov AI. Pharmacological and clinical feature of rebamipide: new therapeutic targets. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):104-11 (In Russ.)]. doi: 10.26442/00403660.2020.02.000569</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Парфенов А.И., Белостоцкий Н.И., Хомерики С.Г. и др. Ребамипид повышает активность дисахаридаз у больных энтеропатией с нарушением мембранного пищеварения. Пилотное исследование. Терапевтический архив. 2019;91(2):25-31 [Parfenov AI, Belostotsky NI, Khomeriki SG, et al. Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(2):25-31 (In Russ.)]. doi: 10.26442/00403660.2019.02.000123</mixed-citation></ref></ref-list></back></article>
